Can P-glycoprotein be inhibited, and what are the implications?
Yes, P-glycoprotein can be inhibited by various compounds, which can increase the bioavailability and efficacy of drugs that are P-gp substrates. Inhibitors such as verapamil, cyclosporine, and quinidine have been studied for their potential to enhance drug delivery and overcome MDR in cancer. However, inhibition of P-gp can also lead to increased toxicity and adverse effects, as the protective efflux of harmful substances is compromised. Therefore, the therapeutic use of P-gp inhibitors requires careful consideration of the risk-benefit ratio.
